To provide a drug for treating patients suffering from dyskinesis by administering at least one kind of adenosine A2A receptor antagonist.
The present invention provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists. The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT (catechol O-methyl transferase) inhibitor and/or a MAO (monoamine oxidase) inhibitor.
MORI AKIHISA
WAKI YUTAKA
OSAWA YUTAKA
KARASAWA HIROSHI
KUWANA YOSHIHISA
JPN6008063198; Ａｎｎａｌｓ ｏｆ Ｎｅｕｒｏｌｏｇｙ Ｖｏｌ．４３, 1998, Ｐ．５０７-５１３